Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by Uknowiton Feb 17, 2021 8:45pm
203 Views
Post# 32592165

RE:From AMZN to ATE - Here's to the ATE Long Haulers!

RE:From AMZN to ATE - Here's to the ATE Long Haulers!

Great post TechMoose and if you're long on Ate you will view today's NR as a great thing. Antibes is now fully funded for Phase 3 trials and I see no way as viewing that as a negative. Worried about dilution? That's a very short term outlook on things imo. Short term investors will see it as a negative but this is a long term investment, one that I've been following for years though I haven't posted here in ages. Anyone that knows anything about Antibes (or anything for that matter) knows that the company had to be cashed up for the next trials. As far as I'm concerned, Ate management have made all the right moves in growing this company. Such signicant support from Cannacord is a sign that they believe in the future of this company. Yes, one of these days we'll be on the Nasdaq but does it matter where the funds come from right now? We needed the $ and we have them now. 

The chart for Ate was stretched and ready for a retrace (in oversold territory). They couldn't have timed this news better imo . No stock goes straight up though we would all like them to.  Guess we'll see what happens at the opening bell tomorrow but in the long run it doesn't matter. This company will do very well no matter what happens for the rest of the week. I'd say GLTA but it's not required! This is one of the safest stocks I have ever been involved in. As TM said, Very well done.  Onward and Upward....To everyone's continued success!

TechMoose wrote: I don't post a lot but I do very much appreciate the chatter that goes on this board (especially you Mugsy)

I am rooting for this company.  John Wallace is a legend and the science is solid.  I started buying ATE a few years ago as a more speculative investment. But I have been much more engaged lately as I see Dan making some very clever moves with the company. 

Ben Horowitz of Andressen Horowitz fame, has some wise words for how CEO's need to focus on 3 big things.  I think Dan Legault looks to be following Ben's playbook:

1) Set a bold vision for the company: Antibe is setting up a very clever strategy of the sulphide technology being a platform play for drug delivery which massively increases the total addressable market and potential valuation.  I've seen them dialing up this narrative a lot more and it's clever.  Even disease states like IBS can now be potentially factored into the scope of their market.

2) Hire the right people and get out of the way: Dan has built a strong team with the addition of players with proven licensing, M&A and regulatory skills.  An added bonus was bringing in Stern to help with much needed IR skills and a broader network they can message to.  They will earn their money.

3) Make sure the company doesn't run out of cash: Clinical trials are a contact sport.  And this was my biggest issue with ATE.  I remember seeing a lot of chatter about sources of cash as insignificant as a potential Citagenix sale and how that could help with the burn.  That won't fund Phase 3.  We were all thinking a lot about runway at the time. ;-). The Nuance deal seemed to come out of nowhere but we have to remember this is the result of a lot of hustle behind the scenes - a very encouraging sign that ATE is now moving to a more advanced commercial stage. There's nothing like real sales to finance a company.  Then the Cannacord news hit today.  That's a lot more gas in the tank. 

Over the past week I've been buying up more ATE and enjoying the ride. 
Here's to the "ATE Long Haulers"......
Dan, John.....and team.  Very well done.  
Onward and Upward....To everyone's continued success!


 

<< Previous
Bullboard Posts
Next >>